


## BACKGROUND AND IMPORTANCE

Recent studies have found that patients with anti PD-L1 treatment, as in the case of pembrolizumab, the incidence of Hepatitis B virus (HBV) reactivation has been increased in those patients with positive HbcAb, recommending the use of prophylaxis to avoid it.

## AIM AND OBJECTIVES

To evaluate the **incidence of Hepatitis B virus reactivation** and the use of prophylaxis under real conditions in patients on Pembrolizumab treatment.

## MATERIAL AND METHODS




### Study variables

**Demographics:** gender, age, weight, height


**Clinics:** serologies in 3 periods (6 months before, during, and one year after starting treatment)

- HbsAb → Antibody against HBV surface antigen
- HbcAb → Antibody against HBV nucleus
- HBV vaccination status

Interpretation of clinical variables	HbsAb	HbcAb
Patient with resolved infection	+	+
Possibly infected patient	-	+
Vaccinated patient	+	-



## RESULTS



- 174 men (66%)
- Average age 65 ± 11 años
- Average weight 69 ± 14 Kg
- Average height 166 ± 10 cm

### Pre-treatment

98 patients (37%) with serology before starting treatment

previous serology	HbsAb	HbcAb
Pos	27	18
Neg	71	80

9 patients (9%) only has positive HbsAb due to vaccination

➔ 18 patients (18%) with a **positive serology** for HbsAb and HbcAb, due to a resolved infection. risk of virus reactivation

### Post-treatment initiation

➔ No patients had reactivation of the virus and in no case was pharmacological prophylaxis prescribed to prevent possible reactivation

## CONCLUSIONS AND RELEVANCE

- Despite having detected patients at risk of HBV reactivation, **no HBV reactivations were detected**. In no case was HBV prophylaxis recommended to prevent reactivation prescribed
- More than half of the patients treated with pembrolizumab didn't have HBV serology, so there may be undetected infected patients.
- It would be advisable to establish systematic serology in patients with pembrolizumab in order to prevent possible reactivation of the virus

## REFERENCES

Ding Z-N, Meng G-X, Xue J-S, Yan L-J, Liu H, Yan Y-C, et al. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol. 2023;149(5):1993-2008

